Mars buys Kellanova for $36 billion
Kellanova鈥檚 portfolio complements the existing Mars portfolio.
Geoff Walden
Research showing added health benefits from GLP-1 drugs
Prospective health benefits from GLP-1 drugs beyond weight loss and lower blood glucose continue to emerge.